The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome by Meun, C. (Cindy) et al.
Clinical Endocrinology. 2019;00:1–9.	 wileyonlinelibrary.com/journal/cen	 | 	1
 
Received:	4	June	2019  |  Revised:	14	October	2019  |  Accepted:	21	October	2019
DOI:	10.1111/cen.14117		
O R I G I N A L  A R T I C L E
The cardiovascular risk profile of middle‐aged women with 
polycystic ovary syndrome
Cindy Meun1  |   Marlise N Gunning2  |   Yvonne V Louwers1 |   Henrike Peters3 |   
Jolien Roos‐Hesselink4  |   Jeanine Roeters van Lennep5 |   Oscar‐Leonel Rueda Ochoa6,7 |  
Yolande Appelman8 |   Nils Lambalk3 |   Eric Boersma4 |   Maryam Kavousi6 |    







































Objectives: Contradictory	 results	 have	 been	 reported	 regarding	 the	 association	
between	polycystic	ovary	syndrome	(PCOS)	and	cardiovascular	disease	(CVD).	We	
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1  | INTRODUC TION
Cardiovascular	disease	(CVD)	is	the	leading	cause	of	morbidity	and	






















atherosclerosis	 can	 be	 detected.	 Carotid	 intima‐media	 thickness	





















suring	cIMT.	 In	addition,	we	assessed	differences	 in	 the	estimated	








hormonal	 evaluation	 and	 a	 transvaginal	 ultrasonography	 to	 assess	
ovarian	volume	and	follicle	count.	This	protocol	has	been	described	in	
detail	elsewhere	22	Diagnosis	of	PCOS	was	based	on	the	Rotterdam	
criteria	 and	established	during	 the	 reproductive	years.10	According	
to	these	criteria,	PCOS	is	diagnosed	when	either	two	or	three	of	the	
key	 features	are	present:	ovulatory	dysfunction,	polycystic	ovarian	
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The	 control	 group	 was	 derived	 from	 the	 Rotterdam	 Study,	 a	
prospective	 population‐based	 cohort	 study	 focusing	 on	 health	
and	 diseases	 in	 the	 elderly.	 We	 selected	 200	 women	 included	
in	 the	 third	 cohort	of	 the	Rotterdam	Study.	The	 third	 cohort	 in‐
cludes	 inhabitants	 of	 the	 municipality	 of	 Ommoord,	 Rotterdam	
aged	 >45	 years,	 and	 was	 recruited	 between	 2006	 and	 2008.	
Participants	 are	 examined	 extensively	 at	 the	 research	 centre	
every	3‐5	years.	The	rationale	and	design	of	this	study	have	been	
described	 in	 detail	 elsewhere.23	 All	 participants	 provided	 writ‐
ten	 informed	 consent	 to	 participate	 in	 the	 study	 and	 to	 obtain	
information	 from	their	 treating	physicians.	The	Rotterdam	Study	
has	 been	 approved	 by	 the	 medical	 ethics	 committee	 according	




K E Y W O R D S
cardiovascular	disease	(7),	polycystic	ovary	syndrome
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the	Ministry	 of	Health,	Welfare	 and	 Sports	 of	 the	Netherlands.	
National	trial	registry	number	NTR6831.
2.3 | Endocrine and cardiovascular assessment of 
women with PCOS and controls
On	 the	 day	 of	 the	 assessment,	 fasting	 blood	 samples	 were	 col‐
lected	 and	 assessed.2,24	We	measured	 cholesterols,	 high‐density	
lipoprotein	 (HDL),	 low‐density	 lipoprotein	 (LDL)	 and	 triglyceride	
serum	 levels.	 Furthermore,	 insulin	 and	 glucose	 levels,	 aspartate	
transaminasel	 (ASAT)	 and	 alanine	 transaminase	 (ALAT),	 andro‐
gens,	 gonadotropins,	 sex	 hormone‐binding	 globulin	 (SHBG)	 and	
oestradiol	 (E2)	 levels	 were	 determined.	 Brain	 natriuretic	 peptide	
(NT‐proBNP),	 a	marker	 for	heart	 failure,	was	also	measured.	The	
free	androgen	index	was	calculated	as	(Testosterone/SHBG)*100.	
Waist	 to	hip	 ratio	was	 calculated	as	waist	 circumference/hip	 cir‐
cumference.	 Blood	 pressure	 was	 measured	 once	 in	 cases	 and	
twice	 in	controls,	 in	sitting	position	after	at	 least	 five	minutes	of	
rest	 with	 a	 random‐zero	 sphygmomanometer.	 Insulin	 resistance	
was	assessed	with	 the	homoeostasis	model	 assessment	 (HOMA‐
IR).	 Insulin	was	converted	 to	mU/L,	and	next,	 the	HOMA‐IR	was	
calculated	as:	fasting	serum	insulin	(mU/L)	x	fasting	plasma	glucose	







syndrome	 is	 present	when	 ≥3	 of	 the	 following	 features	 are	 pre‐
sent:	waist	circumference	≥88	cm,	 fasting	glucose	≥	6.1	mmol/L,	
blood	 pressure	 >129/84	 mm	 Hg,	 high‐density	 lipoprotein	 (HDL)	
<1.3	mmol/L	and	triglycerides	(TG)	≥	1.7	mmol/L.	Vitamin	D	defi‐
ciency	was	defined	as	a	25‐OH‐D	serum	of	<50	nmol/L.
2.4 | Carotid intima‐media thickness for women 
with PCOS and controls
We	used	cIMT	to	assess	subclinical	atherosclerosis	 in	middle‐aged	
women	 with	 PCOS	 and	 age‐matched	 controls	 from	 the	 general	





















































All	 statistical	 analysis	were	performed	with	 IBM	SPSS	 statistics	
version	24	 (IBM	Corp.)	and	STATA	version	14.2	 (Station	College).	A	
two‐sided	P	 <	 .05	 denoted	 statistical	 significance.	Baseline	 charac‐
teristics	were	presented	as	mean	(standard	deviation	[SD])	or	median	
(interquartile	 range	 [IQR])	 for	 continuous	 variables	 and	 as	 propor‐
tions	 (%)	 for	 dichotomous	 variables.	 Continuous	 variables	 with	 a	
normal	distribution	were	compared	with	the	student	t	test	and	with	
Mann‐Whitney	U	 for	 nonnormally	 distributed	 variables.	Chi‐square	
test	or	Fisher's	exact	test	were	used	for	categorical	variables.	Linear	




eliminate	 the	 effect	 of	 possible	 confounders,	we	 adjusted	 for	BMI,	




peated	 all	 the	 analyses	 to	 examine	 the	 effect	 of	 BMI	 on	 the	 car‐
diometabolic	profile	of	women	with	PCOS.
3  | RESULTS
3.1 | General and cardiometabolic characteristics







irregularities	 in	the	past	 (69.8%	vs	12.5%	[P	<	 .001]).	Compared	to	
women	with	PCOS,	a	much	 larger	proportion	of	the	control	popu‐
lation	 was	 already	 postmenopausal	 (40.5%	 vs	 12.6%	 [P	 <	 .001]).	
Women	 with	 PCOS	 were	 less	 often	 smokers	 (41.5%	 vs	 64.8%	
[P	<	 .001])	and	had	more	often	attended	higher	general	education	
or	university	 (P	<	 .001).	The	 free	androgen	 index	was	significantly	
higher	 in	 women	with	 PCOS	 (1.9	 IQR	 1.2‐2.9	 vs	 1.2,	 IQR	 0.8‐1.7	
[P	<	.001]),	as	well	as	serum	levels	of	E2	 (P	=	.028),	whereas	SHBG	
levels	were	significantly	lower	(P	<	.001).
We	 observed	 a	 higher	 BMI	 (28.4,	 IQR	 23.8‐32.9	 vs	 26.3,	 IQR	
23.7‐29.8	[P	=	.015]),	higher	SBP	(130.0,	IQR	120.0‐140.0	vs	122.0,	
IQR	112.0‐136.0	[P	=	.003])	and	increased	waist	circumference	(93.0,	
IQR	 84.5‐107.0	 vs	 85.9,	 IQR	 79.5‐94.6	 [P	 <	 .001])	 in	women	with	
PCOS.	Moreover,	the	prevalence	of	hypertension	(48.2%	vs	26.5%	














adjusting	 for	 BMI,	 smoking,	 SBP,	 education,	 measurement	 centre	
and	menopausal	status,	we	found	that	PCOS	was	associated	with	a	
lower	cIMT	β	(95%CI)	−0.212	(−0.283‐0.142,	P	<	.001).





















ence.	 The	prevalence	of	major	 risk	 factors	 for	CVD	or	CVD	 itself	
was	not	increased,	and	we	found	no	evidence	for	more	severe	ath‐
erosclerosis	in	women	suffering	from	PCOS.	Finally,	the	aggregated	
measure	 of	 10‐year	 CVD	 risk	 and	 overall	 performance	 on	 cardio‐







in	 lipid	 levels	 of	women	with	 PCOS	 and	 age‐matched	 controls.	 In	
addition,	neither	HOMA‐assessed	 insulin	 resistance,	nor	 the	prev‐
alence	of	type	II	diabetes,	metabolic	syndrome	or	CVD	was	signifi‐
cantly	increased	at	the	age	of	50,	despite	of	a	higher	BMI	and	blood	
pressure	 in	 women	 with	 PCOS.	 Atherosclerosis	 can	 be	 detected	






cardiovascular	health	 score,	used	 to	predict	 longevity	 and	healthy	
ageing,	were	similar	in	women	with	PCOS	and	age‐matched	controls.	
Of	 note,	 repeating	 all	 analyses	 with	 an	 age‐BMI	matched	 control	
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TA B L E  1  Characteristics	of	the	total	study	population
 PCOS (N = 200) Control (N = 200) P‐value
General/Obstetric	parameters
Age	(years) 50.5	(5.5) 51.0	(5.2) .35
BMI	(kg/m2) 28.4	(23.8‐32.9) 26.3	(23.7‐29.8) .02
Ethnicity	(Northern‐European) 170	(85.4%) 175	(87.5%) .50
Ever	smoker 78	(41.5%) 129	(64.8%) <.001
Age	at	menarche	(years) 13.7	(2.6) 12.8	(1.6) <.001
Postmenopausal 25	(16.0%) 81	(40.5%) <.001
OCP	use	(ever) 166	(83.4%) 182	(91%) .02









Waist	(cm) 93.0	(84.5‐107.0) 85.9	(79.5‐94.6) <.001
Hip	(cm) 107.0	(99.5‐114.0) 106.5	(100.8‐112.6) .68
Waist/Hip	ratio 0.88	(0.83‐0.93) 0.81	(0.77‐0.86) <.001
Cardiometabolic	parameters
Systolic	BP	(mm	Hg) 130.0	(120.0‐140.0) 122	(112.0‐136.0) <.01
Diastolic	BP	(mm	Hg) 82.7	(11.3) 81.2	(11.3) .19
Hypertension 96	(48.2%) 53	(26.5%) <.001
Prevalent	CVD 3	(1.5%) 3	(1.5%) 1.00
Lipid	lowering	medication 13	(6.5%) 31	(15.6%) <.01
Total	cholesterol	(mmol/L) 5.3	(4.5‐6.0) 5.3	(4.8‐6.1) .44
HDL	cholesterol	(mmol/L) 1.5	(1.2‐1.8) 1.5	(1.2‐1.8) .68
LDL	cholesterol	(mmol/L) 3.3	(2.7‐4.0) 3.1	(2.6‐3.9) .42
Triglycerides	(mmol/L) 1.0	(0.8‐1.6) 1.1	(0.8‐1.5) .35
ASAT	(U/L) 22.0	(19.0‐25.0) 21.0	(18.0‐23.0) .09
ALAT	(U/L) 21.0	(16.0‐30.0) 20.0	(17.0‐25.0) .38
Gamma‐GT	(U/L) 20.0	(15.0‐29.0) 17.0	(13.0‐27.0) .02
NT‐pro‐BNP	(pmol/L) 7.0	(4.0‐13.0) 6.2	(4.1‐11.1) .40
Elevated	NT‐pro‐BNP	(>15	pmol/L) 27	(14.2%) 27	(18.8%) .26
Insulin	(pmol/L) 74.0	(47.0‐117.0) 72.0	(55.0‐105.0) .83
Glucose	(mmol/L) 5.3	(5.0‐5.7) 5.1	(4.8‐5.5) .02
HOMA‐IR 2.68	(1.54‐4.33) 2.43	(1.71‐3.69) .65
Diabetes 22	(11.1%) 13	(6.5%) .11
Metabolic	syndrome	(NCEP	definition) 45	(25.0%) 34	(17%) .06
Mean	carotid	cIMT	(um) 612.8	(93.6) 721.7	(118.4) <.001
Endocrine	parameters
FAI 1.9	(1.2‐2.9) 1.2	(0.8‐1.7) <.001
Testosterone	(nmol/L) 0.9	(0.6‐1.2) 0.8	(0.6‐1.1) .041
SHBG	(nmol/L) 48.5	(34.3‐70.7) 69.6	(46.7‐100.4) <.001
(Continues)
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turbances	 associated	 with	 PCOS,	 increased	 triglyceride	 levels	 are	
the	 only	 lipid	 abnormality	 still	 detectable	 at	 older	 age.5,6,11,13	 The	
same	pattern	seems	to	apply	to	the	metabolic	syndrome,	which	has	
been	described	to	be	five	times	as	prevalent	in	young	women	with	
PCOS,	but	 to	 remain	only	 two	 times	as	prevalent	after	 the	age	of	
39.5,13	Another	possible	explanation	for	this	could	also	be	that	these	
women	were	already	diagnosed	early	on	during	their	reproductive	
years	 and	 were	 also	 informed	 about	 their	 long‐term	 health	 risks,	
which	they	might	have	adjusted	accordingly	 in	the	years	 following	
initial	diagnosis.
Conflicting	 results	 have	 been	 reported	 on	 cIMT	 and	 CVD	 in	
women	with	 PCOS.3,18,35	 Data	 on	 cIMT	 in	middle‐aged	 and	 older	
women	with	(features	of)	PCOS	are	scarce,	but	most	evidence	sug‐











lipidemia	 were	 considered	 cardiovascular	 diseases	 and	 comprised	





















 PCOS (N = 200) Control (N = 200) P‐value
Androstenedione	(nmol/L) 2.6	(1.9‐3.7) 3.0	(2.1‐4.0) .02
DHEA	(nmol/L) 9.8	(6.1‐14.3) 13.9	(9.5‐20.9) <.001
E2	(pmol/L) 150.5	(41.3‐383.3) 78.8	(18.4‐346.1) .03
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with	clues	suggesting	women	with	PCOS	might	be	able	to	compen‐








with	 PCOS	 and	 associated	 with	 cardiometabolic	 abnormalities	 at	
a	 younger	 age.	 In	 the	past,	 hyperandrogenism	was	 suggested	 as	 a	
main	driver	 for	 the	CVD	risk	 in	PCOS.2,34	The	effects	of	hyperan‐




All	 of	 these	 proposed	mechanisms	 could	 protect	 women	with	
PCOS	from	developing	CVD.	Despite	of	 their	unfavourable	profile	
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